杭州倍特生物医药

Hangzhou Better Biotech is a specialized subsidiary of Sichuan Better Pharmaceutical, focused on the research, development, and large-scale manufacturing of high-end biological drugs and complex formulations. The company maintains a strong strategic focus on metabolic disorders, having successfully commercialized key insulin analogs including insulin glargine and insulin aspart. Beyond its established diabetes portfolio, Hangzhou Better Biotech is advancing a pipeline of GLP-1 receptor agonists and other biosimilars targeting oncology and immunology. Operating from a state-of-the-art GMP-compliant facility in Hangzhou, the company serves as the primary biopharmaceutical innovation hub for its parent group.